Business
Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD
New data regarding the mechanism of action of belapectin to inhibit galectin-3Unique pharmacokinetic profile of belapectin in patients with hepatic
About this update from Galectin Therapeutics Inc.
[{"type":"text","content":"New data regarding the mechanism of action of belapectin to inhibit galectin-3Unique pharmacokinetic profile of belapectin in patients with hepatic insufficiencyInnovating in Liver Cirrhosis: Belapectin’s NAVIGATE phase 2b/3 study designNew data regarding correlation between routine liver tests and portal hypertensionImpact of NASH cirrhosis on patients’ Quality of LifeUse of Artificial Intelligence to further understand the histology of Liver Cirrhosis NORCROSS, Ga., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it will present six scientific abstracts at The Liver Meeting™ 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), to be held virtually from November 12 to 15, 2021. “Much of the focus on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has been on preventing the progression to liver cirrhosis, but there has been little focus on treating those affected with actual NASH cirrhosis. We are dedicated to change this situation, and our objective is to bring new solutions to cirrhotic patients, as they are in greatest need of therapeutic options,” said Pol Boudes, M.D., Chief Medical Officer for Galectin Therapeutics. “Our work in developing belapectin, our galectin-3 inhibitor, focuses on the prevention of esophageal varices in NASH cirrhosis patients. We have generated a wealth of new data on NASH cirrhosis and portal hypertension and we are pleased to share this research at The Liver Meeting. Also, NAVIGATE, our phase 2b/3 global study, represents a new way to undertake clinical research in cirrhotic patients, and we hope this will trigger the interest of the hepatic community and drug developers around the world in addressing this devastating disease.” These abstracts will be available for viewing by attendees on the AASLD website and are also featured in the October supplement to the AASLD journal, Hepatology. Presentation Details Title: Mechanism of galectin-3 binding by belapectin, a galectin-3 inhibitor developed for NASH cirrhosisGalectin-3, a glycan binding protein, plays a central role to foster liver inflammation and fibrosis in NASH cirrhosis. Belapectin is a galectin-3 inhibitor in development for NASH cirrhosis. We use heteronuclea...